Can CBD work as a new kind of antipsychotic?

Emerging evidence from preclinical, experimental, neuroimaging, and clinical studies suggests CBD has antipsychotic properties through mechanisms distinct from current medications.

Davies, Cathy et al.·Therapeutic advances in psychopharmacology·2019·Moderate EvidenceReview
RTHC-02000ReviewModerate Evidence2019RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Review
Evidence
Moderate Evidence
Sample
Not reported

What This Study Found

CBD shows potential as a novel antipsychotic with a unique non-dopamine-D2 mechanism of action. Clinical evidence suggests possible benefits for positive, negative, and cognitive symptoms of psychosis, with a favorable safety and tolerability profile.

Key Numbers

Psychotic disorders like schizophrenia contribute substantially to the global burden of disease. D2 antagonists have been the mainstay since the 1950s, but a significant proportion of patients don't achieve adequate remission.

How They Did This

Narrative review synthesizing preclinical studies, human experimental and neuroimaging research, and clinical trials evaluating CBD's antipsychotic effects, safety, tolerability, and potential mechanisms.

Why This Research Matters

Current antipsychotics all work by blocking dopamine D2 receptors, causing significant side effects. A substantial number of patients don't respond adequately. CBD represents a fundamentally different pharmacological approach that could help treatment-resistant patients.

The Bigger Picture

If CBD proves effective as an antipsychotic, it would be the first new class of antipsychotic medication with a non-D2 mechanism in decades. This could transform treatment options for the millions of people living with psychotic disorders worldwide.

What This Study Doesn't Tell Us

This is a narrative review, not a systematic review or meta-analysis. The clinical evidence base for CBD as an antipsychotic is still limited, with few large-scale randomized controlled trials completed.

Questions This Raises

  • ?What is the optimal dose of CBD for antipsychotic effects?
  • ?Can CBD be combined with traditional antipsychotics for enhanced benefit?
  • ?Which specific patient populations would benefit most?

Trust & Context

Key Stat:
CBD operates through a non-D2 mechanism unlike all current antipsychotics
Evidence Grade:
Moderate: review synthesizes multiple lines of evidence including some clinical trials, but large-scale RCTs are limited.
Study Age:
Published in 2019.
Original Title:
Cannabidiol as a potential treatment for psychosis.
Published In:
Therapeutic advances in psychopharmacology, 9, 2045125319881916 (2019)
Database ID:
RTHC-02000

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study

Summarizes existing research on a topic.

What do these levels mean? →

Frequently Asked Questions

Is CBD approved as an antipsychotic?

No. While research shows promise, CBD is not approved for treating psychosis. The evidence reviewed here is primarily from early-stage clinical trials and preclinical research.

How is CBD different from current antipsychotics?

All current antipsychotics work by blocking dopamine D2 receptors. CBD appears to work through entirely different mechanisms, which could mean fewer of the movement-related and metabolic side effects associated with D2 blockers.

Read More on RethinkTHC

Cite This Study

RTHC-02000·https://rethinkthc.com/research/RTHC-02000

APA

Davies, Cathy; Bhattacharyya, Sagnik. (2019). Cannabidiol as a potential treatment for psychosis.. Therapeutic advances in psychopharmacology, 9, 2045125319881916. https://doi.org/10.1177/2045125319881916

MLA

Davies, Cathy, et al. "Cannabidiol as a potential treatment for psychosis.." Therapeutic advances in psychopharmacology, 2019. https://doi.org/10.1177/2045125319881916

RethinkTHC

RethinkTHC Research Database. "Cannabidiol as a potential treatment for psychosis." RTHC-02000. Retrieved from https://rethinkthc.com/research/davies-2019-cannabidiol-as-a-potential

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.